Immune-checkpoint inhibitors: long-term implications of toxicity
The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …
treatment, enabling the possibility of long-term survival in patients with metastatic disease …
Targeting cytokine and chemokine signaling pathways for cancer therapy
Cytokines are critical in regulating immune responses and cellular behavior, playing dual
roles in both normal physiology and the pathology of diseases such as cancer. These …
roles in both normal physiology and the pathology of diseases such as cancer. These …
Molecular pathways of colon inflammation induced by cancer immunotherapy
Checkpoint blockade with antibodies specific for the PD-1 and CTLA-4 inhibitory receptors
can induce durable responses in a wide range of human cancers. However, the …
can induce durable responses in a wide range of human cancers. However, the …
Understanding and treating the inflammatory adverse events of cancer immunotherapy
During the past decade, immunotherapies have made a major impact on the treatment of
diverse types of cancer. Inflammatory toxicities are not only a major concern for Food and …
diverse types of cancer. Inflammatory toxicities are not only a major concern for Food and …
AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review
M Dougan, Y Wang, A Rubio-Tapia, JK Lim - Gastroenterology, 2021 - Elsevier
Background & Aims Immune checkpoint inhibitors (ICIs) have transformed the treatment
landscape for oncology, leading to durable remissions in a subset of patients, but also a …
landscape for oncology, leading to durable remissions in a subset of patients, but also a …
Moving towards personalized treatments of immune-related adverse events
The enhancement of immune responses upon treatment with immune checkpoint inhibitors
can have the desired outcome of reinvigorating antitumour immune surveillance, but often at …
can have the desired outcome of reinvigorating antitumour immune surveillance, but often at …
Immune checkpoint inhibitor-associated colitis: from mechanism to management
L Tang, J Wang, N Lin, Y Zhou, W He, J Liu… - Frontiers in …, 2021 - frontiersin.org
Immune checkpoint inhibitors (ICIs), as one of the innovative types of immunotherapies,
including programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and …
including programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and …
Holistic approach to immune checkpoint inhibitor-related adverse events
R Poto, T Troiani, G Criscuolo, G Marone… - Frontiers in …, 2022 - frontiersin.org
Immune checkpoint inhibitors (ICIs) block inhibitory molecules, such as cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its …
lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its …
[HTML][HTML] Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic …
J Haanen, M Ernstoff, Y Wang, A Menzies… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Patients with cancer who developed severe, grade 3 or 4 immune-related adverse events
(irAEs) during therapy with immune checkpoint inhibitors are at risk for develo** severe …
(irAEs) during therapy with immune checkpoint inhibitors are at risk for develo** severe …
Predictive biomarkers for checkpoint inhibitor immune-related adverse events
I Les, M Martinez, I Perez-Francisco, M Cabero… - Cancers, 2023 - mdpi.com
Simple Summary Immune-checkpoint inhibitors (ICIs) are increasingly used in the treatment
of cancer, but they cause immune-related adverse events (irAEs) in around 40% of patients …
of cancer, but they cause immune-related adverse events (irAEs) in around 40% of patients …